Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

UK R&D Centre for Antimicrobial Resistance Goes Into Battle

The UK's recently launched AMR Centre has launched two R&D collaborations and plans two more this year.

Business Strategies Commercial

Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets

Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.

Business Strategies Clinical Trials

Immatics $58m Series E To Fund T-Cell Receptor-Based IO Therapies

The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.

Financing Companies

Caterpillar To Butterfly? Ablynx Says Caplacizumab Data Transformational

Belgian Nanobody drug developer Ablynx says it will be transformed by positive Phase III topline HERCULES data on caplacizumab for treating the rare blood-clotting disorder, acquired TTP.

Clinical Trials Companies

Novo Nordisk CSO Thomsen Assesses The Competition In Diabetes

The world of diabetes will increasingly be dominated by Novo Nordisk and Eli Lilly, the Danish group's chief science officer tells Scrip.

Business Strategies Commercial

Autolus Raises $80m To Take T-Cell Engineering To The Next Level

Three-year-old clinical-stage UK biotech Autolus will use its $80m (£59m) Series C financing to advance three dual targeting CAR-T candidates in the clinic and build capacity.

ImmunoOncology Commercial
See All
Advertisement
UsernamePublicRestriction

Register